Get news straight to your inbox by signing up for our free eNewsletters
Aer’s inhaled formulation targets the mucus plugs obstructing COPD patients’ airways.
Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.
3/27/2023
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.
3/21/2023
Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.
Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
Women are often at the forefront of innovation, making up nearly half of the life sciences industry despite a shrinking but persistent wage gap. Inceptor Bio is at the forefront of closing inequality.
3/6/2023
Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.
3/6/2023
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.
2/28/2023
Zymtronix, Inc., a groundbreaking new biotechnology company, today announced that Dr. Thomas Videbaek, biotech industry veteran and former Executive Vice President (EVP) of Novozymes, is joining its Board of Directors.
Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.
Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding.
Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.
2/1/2023
FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, announced they are the fastest rising biotech offering in StartEngine’s history surpassing $1 million of new investments on the first day of its Reg CF offering.
1/30/2023
Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure.
1/19/2023
Selux Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System.
1/17/2023
Oncotelic Therapeutics, Inc announced the launch of Pet2DAO Inc., a wholly owned subsidiary of Oncotelic, and its associated token PDAO.
1/17/2023
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company.
3/21/2023
English
Arabic
Bengali
Chinese (Simplified)
Dutch
French
German
Hindi
Indonesian
Italian
Japanese
Korean
Norwegian
Persian
Polish
Portuguese
Russian
Spanish
Swedish
Turkish
Vietnamese